| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5589629 | Gene | 2017 | 29 Pages |
Abstract
We found that patients with the e14a2 transcript achieved better and faster responses to Imatinib mesylate. In this study, parallel data regarding molecular and cytogenetic responses, impact of transcript type on the probability of recurrence might suggest a general outcome that the type of transcript can be used as a prognostic marker at diagnosis.
Keywords
CCRComplete molecular responseELNWBCsMajor Cytogenetic Responseimatinib mesylateMMREFsCMLCMRMCREvent-free survivaloverall survivalPeripheral bloodAccelerated Phasechronic phaseconfidence intervalChronic myeloid leukemiaInternational scaleClinical outcomeodds ratioMajor Molecular ResponseComplete Cytogenetic Responsewhite blood cells
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Golale Rostami, Mohammad Hamid, Hasan Jalaeikhoo,